The National Institute of Allergy and Infectious Diseases (NIAID) is funding two new phase II trials to examine the safety and acceptability of long-acting, injectable antiretroviral drugs to protect against HIV infection. The HPTN 076 trial will evaluate the safety and acceptability of rilpivirine LA, a long-acting injectable form of the FDA-approved rilpivirine (Janssen Sciences Ireland UC), in 132 women, ages 18 to 45, who are not infected with HIV and who are considered at low-risk for HIV infection.